Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 19;14(3):100519.
doi: 10.1016/j.waojou.2021.100519. eCollection 2021 Mar.

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Andreas Wollenberg  1 , Simon Francis Thomsen  2 , Jean-Philippe Lacour  3 , Xavier Jaumont  4 , Slawomir Lazarewicz  4
Affiliations
Review

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Andreas Wollenberg et al. World Allergy Organ J. .

Abstract

Immunoglobulin E (IgE) plays an essential role in many allergic diseases. This review highlights the role of IgE in atopic dermatitis (AD), a common, chronic, and complex skin inflammation, and the available therapeutic approaches that target IgE in AD. We examine the existing data showing the use of omalizumab, the only biologic anti-IgE therapy available in clinical use, plasma apheresis, and a combination of both therapeutic approaches for the treatment of AD. Existing data on the efficacy of omalizumab in AD are inconclusive. A limited number of randomised controlled studies, few uncontrolled prospective and retrospective reports, as well as multiple case series and case reports observed varying degrees of the efficacy of omalizumab in AD. Omalizumab displays a trend of higher efficacy in AD patients with low IgE levels compared with those with very high-to-extremely high serum IgE concentrations. Plasma apheresis and its combination with omalizumab show good efficacy, even in patients with unusually high serum IgE concentrations. Combining apheresis and anti-IgE treatment may serve as a comprehensive therapeutic approach for patients with elevated levels of IgE. Dedicated clinical studies with robust study designs are needed to establish the therapeutic efficacy of omalizumab in AD.

Keywords: Apheresis; Atopic dermatitis; Biologics; Immunoglobulin E; Omalizumab.

PubMed Disclaimer

Conflict of interest statement

Andreas Wollenberg has received grants, personal fees or nonfinancial support from 10.13039/100006483Abbvie, Almirall, 10.13039/501100010558Beiersdorf, Bioderma, 10.13039/100010795Chugai, Galapagos, 10.13039/501100009754Galderma, Hans Karrer, Leo Pharma, Eli Lilly, L'Oreal, Maruho, 10.13039/501100004628MedImmune, 10.13039/100004336Novartis, 10.13039/100004319Pfizer, 10.13039/100013226Pierre Fabre, 10.13039/100009857Regeneron, 10.13039/501100004286Santen and Sanofi-Aventis. Jean-Philippe Lacour has received grants/research support as an investigator and honoraria, advisory board, or consulting fees from 10.13039/100006483AbbVie, BMS, 10.13039/100008349Boehringer Ingelheim, 10.13039/100006436Celgene, 10.13039/100013988Dermira, 10.13039/501100009754Galderma, Janssen, 10.13039/100004312Eli Lilly and Company, Leo-Pharma, 10.13039/100004334Merck, 10.13039/100004336Novartis, 10.13039/100009857Regeneron, 10.13039/100004337Roche, and 10.13039/100004339Sanofi. Simon Francis Thomsen has been a paid speaker, served on advisory boards and received research support from 10.13039/100006483Abbvie, Almirall, 10.13039/100006436Celgene, Eli Lilly, GSK, Janssen, Leo Pharma, 10.13039/100004336Novartis, 10.13039/100013226Pierre Fabre, 10.13039/100004337Roche, 10.13039/100004339Sanofi and 10.13039/100011110UCB. Xavier Jaumont and Slawomir Lazarewicz are permanent employees of Novartis Pharma AG.

Figures

Fig. 1
Fig. 1
Simplified mechanism of AD and the role of IgE. Antigen penetration through damaged skin and presentation via APCs leads to a Th2 response. The resulting IgE production against the antigen can lead to degranulation of mast cells in the presence of the external antigen or food allergens causing a local inflammatory response and recruitment of other inflammatory cells such as EoS. LCs and IDCs activated via recognizing pathogen-derived antigens, promote Th1 and Th2 driven immune responses in acute AD lesions. Omalizumab, by neutralizing IgE, can inhibit mast cell degranulation and dendritic cell activation. AD, atopic dermatitis; EoS, eosinophils; IDC, inflammatory dendritic cells; IgE, immunoglobulin E; IL, interleukin; LC, Langerhans cells; Th2, T helper cell.
Fig. 2
Fig. 2
Patient population, their baseline IgE levels, and corresponding clinical outcome of treatment of AD with omalizumab in terms of percentage change from baseline in SCORAD/DLQI/Pruritus/EASI scores in various studies. Size of the dots are proportional to the number of patients analysed. Hotze et al., 2013 showing deterioration consists of all patients with FLG mutations DLQI, dermatological life quality index; EASI, Eczema Area and Severity Index; FLG, filaggrin gene; IgE, immunoglobulin E; SCORAD, scoring atopic dermatitis.
See this image and copyright information in PMC

References

    1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metabol. 2015;66(Suppl 1):8–16. - PubMed
    1. Thomsen S.F. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250. 354250. - PMC - PubMed
    1. Tsai T.F., Rajagopalan M., Chu C.Y. Burden of atopic dermatitis in Asia. J Dermatol. 2019;46:825–834. - PubMed
    1. Silverberg J.I. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35:283–289. - PubMed
    1. Andersen L., Nyeland M.E., Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol. 2020;182:1007–1016. - PMC - PubMed

LinkOut - more resources